Novera CJC-1295 (no DAC) 5mg

CJC-1295 no DAC – also known as Modified GRF (1-29) or Mod GRF 1-29 – is a synthetic peptide analog of growth hormone releasing hormone (GHRH) that has been extensively evaluated in research models for its ability to stimulate growth hormone release from the pituitary gland through selective GHRH receptor activation. With a molecular weight of 3,367.9 g/mol and four strategic amino acid substitutions that dramatically improve enzymatic stability, CJC-1295 (No DAC) is a modified GHRH analog that produces sharp, pulsatile GH secretion patterns of particular interest to researchers studying body composition, protein synthesis, tissue repair, and metabolism.

CJC-1295 and Ipamorelin are available for research purposes only. This compound is supplied by FillerSupplies.com exclusively for licensed researchers and laboratory professionals – it is not intended for human consumption, clinical treatment, or diagnostic use. All information presented below reflects published preclinical and in-vitro findings and is provided to support controlled experimental conditions in qualified research settings.

General Information About CJC-1295 no DAC

CJC-1295 no DAC is a 29-amino acid synthetic peptide derived from the biologically active N-terminal fragment of human GHRH (residues 1–29), historically referred to as GRF(1-29) or Sermorelin. CJC-1295’s molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂, and CJC-1295 has a molecular weight of approximately 3367.9 g/mol. Its complete amino acid sequence reads:

Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–NH₂

This sequence contains the characteristic segments – Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg – and incorporates four critical substitutions relative to native GRF(1-29): D-Alanine at position 2 (replacing L-Ala), Glutamine at position 8 (replacing Asn), Alanine at position 15 (replacing Gly), and Leucine at position 27 (replacing Met). These modifications confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, reduce oxidative and deamidation liability, and extend the functional half-life from approximately 2–10 minutes (native GHRH) to roughly 30 minutes in mammalian research models.

CJC-1295 stimulates growth hormone release via GHRH receptors – specifically the class II G-protein-coupled receptor expressed on pituitary somatotrophs. Upon binding, CJC-1295 enhances GH synthesis through the cAMP-PKA pathway: receptor activation triggers Gₛ protein coupling, adenylyl cyclase activation, elevated intracellular cAMP, protein kinase A (PKA) activation, and subsequent phosphorylation of CREB transcription factors that drive GH gene expression. Calcium channel opening simultaneously promotes exocytosis of stored GH granules, producing rapid onset of hormone release.

The critical difference between CJC-1295 no DAC and the DAC variant lies in the absence of the drug affinity complex – a maleimidopropionic acid-lysine linker that covalently binds serum albumin at Cys-34. Without this albumin anchor, CJC-1295 (No DAC) has a shorter duration of action than DAC-modified CJC-1295, undergoing rapid renal filtration and proteolytic clearance. While the DAC variant achieves a half-life of approximately 5.8–8.1 days in human subjects, CJC-1295 no DAC produces acute, pulsatile GH elevations peaking at 30–60 minutes and declining over 2–4 hours – a pattern that more closely mirrors natural growth hormone secretion rhythms from the pituitary gland.

CJC-1295 no DAC Use in the Research Setting

CJC-1295 no DAC is supplied as a dry lyophilized powder for research and laboratory use only, enabling precise reconstitution under controlled experimental conditions.

1. Growth Hormone Release Stimulation

The four amino acid substitutions in modified GRF (1-29) confer dramatically enhanced potency compared to native GHRH. In rat pituitary cell studies, this modified sequence demonstrated up to 49-fold greater growth hormone releasing activity relative to unmodified GRF(1-29), attributable to the compound’s increased resistance to enzymatic degradation and preserved receptor-binding conformation.

The GH secretion pattern produced by CJC-1295 no DAC is sharply pulsatile: growth hormone levels rise rapidly after administration, peak within 30–60 minutes, and return to baseline within hours. This pattern is physiologically relevant because natural growth hormone secretion occurs in discrete pulses rather than through continuous stimulation. Researchers studying the interaction between pulsatile GH release and downstream endpoints – including IGF-1 activation, body composition changes, and recovery markers – find the no-DAC variant particularly useful for mimicking endogenous secretory dynamics.

<em>Important to Know:</em>

2. Metabolic and Anabolic Research Applications

Preclinical studies have demonstrated that GHRH analog administration influences multiple metabolic endpoints. CJC-1295 may enhance muscle development and lean body mass, and CJC-1295 can support bone function and density – findings observed in animal models including GHRH knockout mice where daily CJC-1295 administration restored body weight, linear growth, and normal body composition. The frequency of dosing significantly influenced outcomes: daily administration normalized growth parameters, while every-48-hour or every-72-hour dosing produced intermediate effects.

Researchers often combine CJC-1295 no DAC with the selective pentapeptide ipamorelin to investigate synergistic GH release via complementary mechanisms. While CJC 1295 activates the GHRH receptor pathway, ipamorelin activates ghrelin receptors (GHS-R1a) through an independent signaling cascade. CJC-1295 and Ipamorelin activate GH release through complementary pathways, and this CJC 1295 ipamorelin peptide combination produces amplified GH pulses without continuous elevation – a research paradigm useful for studying fat loss, protein synthesis, and recovery in research models. Ipamorelin has a molecular weight of approximately 711.9 g/mol and Ipamorelin’s molecular formula is C₃₈H₄₉N₉O₅, making it structurally distinct from the larger GHRH analog.

Notably, Ipamorelin may improve bowel movement and gastric function in the digestive system, and Ipamorelin may increase appetite and promote weight gain – effects mediated through ghrelin receptor activation that are absent when CJC-1295 no DAC is used alone. CJC-1295 may improve cognitive function and sleep quality, with improved sleep and better sleep patterns reported as downstream effects of optimized GH pulsatility in preclinical observations.

“Because the albumin anchor is missing, the No-DAC form is rapidly eliminated, producing sharp GH pulses that more closely mimic physiological secretion rather than sustained elevation – making it the preferred selective growth hormone secretagogue for pulsatility-focused research.”

3. Receptor Selectivity and Signaling Pathways

CJC-1295 no DAC demonstrates high selectivity for the GHRH receptor with no meaningful activation of the ghrelin receptor (GHS-R1a). This selectivity means the compound does not directly stimulate appetite, cortisol release, or ACTH secretion – pathways associated with GHRP compounds and mixed growth hormone secretagogue peptides.

The downstream signaling cascade proceeds through the cAMP/PKA/CREB axis as the primary pathway, with secondary engagement of MAPK/ERK pathways. Receptor activation yields both immediate GH exocytosis (via calcium influx) and upregulated GH gene expression through CREB phosphorylation and transcription factors activation, supporting sustained somatotroph output over subsequent hours. Ipamorelin increases GH release without affecting ACTH levels, which further supports the rationale for combining these compounds in research – CJC 1295 ipamorelin protocols leverage both the GHRH receptor pathway and ghrelin receptor pathway without stimulating the corticotropic axis.

In contrast to non-selective secretagogues that may provoke cortisol and prolactin release, CJC-1295 no DAC maintains a clean pharmacological profile in preclinical models, making it valuable for researchers seeking to isolate GH-specific effects on insulin resistance, metabolism, and skin health endpoints without confounding hormonal interaction.

4. Stability and Pharmaceutical Properties

The D-Alanine substitution at position 2 is the primary modification conferring DPP-IV resistance, blocking the enzyme’s cleavage of the Tyr¹–Ala² bond that rapidly destroys native GHRH. The additional substitutions at positions 8, 15, and 27 protect against deamidation, oxidation, and broader proteolytic degradation, collectively extending functional half-life while preserving the α-helical structure essential for receptor binding affinity.

CJC-1295 and Ipamorelin are synthesized using HPLC methods, ensuring high compound integrity. Storage of lyophilized peptides requires desiccated conditions at −20 °C or colder for long-term stability. Reconstitution follows a simple process: sterile bacteriostatic water or appropriate buffer is added gently along the vial wall – avoiding vortexing to prevent aggregation. After reconstitution, the solution should be refrigerated at 2–8 °C and used within a limited period (typically days to weeks, depending on the solvent system). These handling requirements are consistent across most research-grade peptides and should be evaluated within each laboratory’s standard operating procedures.

Structural analyses confirm that CJC-1295 no DAC retains the α-helical conformation necessary for GHRH receptor engagement. The four modifications preserve the receptor-binding domain topology of the native ligand while substantially improving pharmacokinetic properties – a design approach that balances potency with practical utility in research settings.

Buy CJC-1295 no DAC Online at FillerSupplies.com

FillerSupplies.com is a trusted source where researchers and licensed professionals can buy CJC-1295 no DAC, as well as buy ipamorelin CJC 1295 combined formulations, with confidence in product authenticity and supply chain integrity. CJC-1295 (No DAC) + Ipamorelin costs around $90.00, and orders placed by 12 PM PST ship the same day. For those asking where can I buy CJC 1295 from a reliable supplier, or searching for the best place to buy CJC 1295 ipamorelin, FillerSupplies.com offers:

• Authentic, certified products – original, quality-controlled compounds, warehouses worldwide.

• 11 years of reliability & trust – established supplier on the market since 2006.

• Temperature-controlled shipping – thermal packaging with ice gel / cold packs preserves stability.

• Express worldwide shipping – next-day dispatch, global delivery.

• Best wholesale prices – tiered bulk discounts and price-match guarantee.

• Privacy guaranteed; expert support at (888) 392-6640, WhatsApp and email, Mon–Fri 10 am–6 pm EST.

• Supplied for research use only, to licensed professionals.

All CJC 1295 products available through FillerSupplies.com are intended for research purposes only and are supplied exclusively to qualified professionals with appropriate institutional credentials. Contact the care team for volume pricing or technical inquiries related to your health goals in the laboratory setting.